Fortschritte in der Pharmakotherapie

  • Timothy E. Wilens
  • Ralf W. Dittmann
Conference paper

Zusammenfassung

Neben der Beratung und den psychosozialen Interventionen nimmt die Pharmakotherapie im multimodalen Therapiekonzept von ADS/ADHS eine zentrale Rolle ein. Derzeit gelten Stimulanzien wie Methylphenidat als Mittel der Wahl. Neue medikamentöse Optionen wie Atomoxetin versprechen zukünftig möglicherweise Fortschritte in der Behandlung von ADS/ADHS.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Abikoff H, Hechtman L (1996) in Jensen PS, Hibbs ED (eds.) Psychosocial treatment for child and adolescent disorders: empirically based approaches, 341–69, American Psychological Association, Washington DCCrossRefGoogle Scholar
  2. 2.
    Wilens TE et al. (2003) Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111(1): 179–8PubMedCrossRefGoogle Scholar
  3. 3.
    Zametkin AJ, Ernst M (1999) Problems in the management of attention-deficit-hyperactivity disorder. N Engl J Med 340(1): 40–6PubMedCrossRefGoogle Scholar
  4. 4.
    Barkley RA (1998) Attention-Deficit/Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. Guilford Press, New York; Barkley RA et al. (1996) Psychological adjustment and adaptive impariments in young adults with ADHD. Journal of Attention Disorders 1: 41–54; Cunningham CE et al. (1985) A developmental dose-response analysis of the effects of methylphenidate on the peer interactions of attention deficit disordered boys. J Child Psychol Psychiatry 26(6): 955–71Google Scholar
  5. 5.
    Michelson D et al. (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159(11): 1896–901PubMedCrossRefGoogle Scholar
  6. 6.
    Prince JB et al. (2000) A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 10(3): 193–204PubMedCrossRefGoogle Scholar
  7. 7.
    Wilens TE et al. (2001) A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158(2): 282–8PubMedCrossRefGoogle Scholar
  8. 8.
    Hunt RD et al. (1985) Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 24(5): 617–29PubMedCrossRefGoogle Scholar
  9. 9.
    Hunt RD et al. (1986) The therapeutic effect of Clonidine in attention deficit disorder with hyperactivity: a comparison with placebo and methylphenidate. Psychopharmacol Bull 22(1): 229–36PubMedGoogle Scholar
  10. 10.
    Kurlan R et al. (2002) Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58(4): 527–36Google Scholar
  11. 11.
    Michelson D et al. (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108(5): E83PubMedCrossRefGoogle Scholar
  12. 12.
    Kratochvil CJ et al. (2002) Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 41 (7): 776–84PubMedCrossRefGoogle Scholar
  13. 13.
    Spencer T et al. (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155(5): 693–5PubMedGoogle Scholar
  14. 14.
    Wilens TE et al. (1999) A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 156(12): 1931–7PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg New York 2003

Authors and Affiliations

  • Timothy E. Wilens
    • 1
  • Ralf W. Dittmann
    • 2
  1. 1.BostonUSA
  2. 2.Bad HomburgHamburgDeutschland

Personalised recommendations